STOCK TITAN
  1. Home
  2. News
  3. EVFMD

evfmd - $evfmd STOCK NEWS

Welcome to our dedicated page for evfmd news (Ticker: $evfmd), a resource for investors and traders seeking the latest updates and insights on evfmd stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect evfmd's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of evfmd's position in the market.

News
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
Rhea-AI Summary
Evofem Biosciences successfully renegotiates Phexxi rebate with Medi-Cal, improving by 7.4% and providing price protection against future increases. The renegotiated rebate will take effect on July 1, 2024, benefiting over 15.4 million beneficiaries in California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.25%
Tags
none
-
News
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
Rhea-AI Summary
Evofem Biosciences, Inc. (EVFMD) celebrates the removal of Prior Authorization for Phexxi contraceptive, expanding coverage for 1.8 million Washingtonians across all Medicaid plans. The move coincides with the surge in testosterone levels for fans of the victorious Washington Huskies, following their Sugar Bowl win, and the upcoming 2024 College Football National Championship. Phexxi, the FDA-approved hormone-free contraceptive gel, is now more accessible to women under the Washington State HCA's Managed Medicaid and Fee for Service Medicaid plans, marking a significant milestone for Evofem Biosciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
-
News
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
Rhea-AI Summary
Evofem Biosciences, Inc. (EVFM) and Aditxt, Inc. (ADTX) have announced a definitive agreement for Aditxt to acquire Evofem in a transaction valued at approximately $100 million. Evofem, the creator of the FDA-approved hormone-free contraceptive gel, Phexxi®, has posted $13.4 million in net sales for the first nine months of 2023. Aditxt aims to accelerate Evofem into the global non-hormonal birth control market, projected to grow from $27.7 billion in 2022 to $52.2 billion by 2031.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.26%
Tags
acquisition
News
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
Rhea-AI Summary
Evofem Biosciences announces preliminary results for Q3 2023, with sequential growth in net product sales of Phexxi contraceptive gel. Selling and marketing expenses significantly reduced, leading to a decrease in operating loss. Notable developments include successful negotiation of a fourth amendment to Securities Purchase and Security Agreement and withdrawal of generic drug maker's application for FDA approval. Evofem on track for third consecutive year of net product sales growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.43%
Tags
earnings
-
News
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-33.33%
Tags
none
Stock EVFMD logo
evfmd

OTC:EVFMD

EVFMD Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

EVFMD Stock Data

1.99M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About EVFMD

evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.